033 Drug eluting stent percutaneous angioplasty

Overview of Intracoronary Brachytherapy for in-Stent Restenosis of a Drug-Eluting Stent

Percutaneous coronary intervention with stenting is considered recently as the most common procedure for the treatment of symptomatic coronary. The article reviewed 41 studies published during 1997-2019 on intracoronary brachytherapy for in-stent restenosis of a drug-eluting stent. Intracoronary radiation therapy was finally confirmed in the setting of in-stent restenosis using as adjunctive th...

Drug-eluting stent coatings.

This paper reviews the development of coronary stents from a polymer scientist's view point, and presents the first results of an interdisciplinary team assembled for the development of new stent systems. Poly(styrene-b-isobutylene-b-styrene) block copolymer (SIBS), a nanostructured thermoplastic elastomer, is used in clinical practice as the drug-eluting polymeric coating on the Taxus coronary...

Drug-Eluting Stent Restenosis

OBJECTIVES We sought to determine if the angiographic pattern of in-stent restenosis in drug-eluting stents (DES) maintains its prognostic importance. BACKGROUND The pattern of restenosis in the bare-metal stent era had a significant impact on therapeutic outcomes. METHODS We identified a total of 250 consecutive restenotic lesions in 203 patients (66.4% sirolimuseluting stents and 33.6% paclit...

Drug-eluting stent thrombosis

OBJECTIVES We compared the risk of stent thrombosis (ST) after drug-eluting stents (DES) versus bare-metal stents (BMS), and tested the hypothesis that the risk of DES thrombosis is related to stent length. BACKGROUND Whether DES increase the risk of ST remains unclear. Given the very low restenosis rate after drug-eluting stenting, longer stents are frequently implanted for the same lesion len...

The first reported case of pulmonary vein stenosis treated by percutaneous angioplasty with self-apposing drug-eluting stent implantation.